AstraZeneca Etcamah trial fails primary endpoint
AstraZeneca said its Etcamah plus palbociclib study in ER-positive, HER2-negative advanced breast cancer did not meet its primary endpoint.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.